Navigation Links
Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
Date:6/6/2011

this study were presented today at the 2011 Annual Meeting of ASCO and the full ASCO presentation is posted on our website.

Two ongoing studies, initiated in Q1 2011, are evaluating PCI-32765 in combination with standard therapies for CLL/SLL. We have enrolled 34 patients in these studies and anticipate completing enrollment in 2011.

From these studies, we expect to be able to analyze initial 3-month safety data for ofatumumab/PCI-32765 and bendamustine/rituximab/PCI-32765 in the second half of 2011. To date the preliminary safety data from these combination studies suggests that these combinations are likely to be safe.

Based on the significant single-agent activity in CLL/SLL from the ongoing Phase IB/II trial, and contingent upon confirmation of 3-month combination safety data, Phase III planning is currently underway. We expect to initiate a Phase III study in CLL/ SLL in the first half of 2012.  

-- Mantle Cell Lymphoma (MCL)
A Phase II study of single-agent PCI-32765 in relapsed or refractory MCL (PCYC-1104) began enrolling patients in late February 2011. To date, we have enrolled 30 patients on this trial and anticipate completing enrollment by the end of calendar 2011. Initial review of early data from this ongoing study suggests that the high overall response rate observed in Phase I is likely to be similar in Phase II. We anticipate submitting an abstract with interim results for presentation at the 2011 American Society of Hematology (ASH) Meeting. Contingent upon the ongoing analysis of PCYC-1104, we will soon begin Phase III planning in MCL. We anticipate that a Phase III study will be initiated in 2012.

-- Diffuse Large B-Cell Lymphoma (DLBCL)
A multicenter, open-label, Phase II study of PCI-32765 in patients with relapsed or refractory DLBCL (PCYC-1106) began enrollment in May 2011. This study is designed to assess the activity of PCI-32765 in two genetically distinct subt
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness & ... Center by the Medical Fitness Association, a non-profit organization ... their full potential. The Cadence Fitness & Health Center ... suburbs and second in the Chicagoland area. ...
(Date:1/15/2014)... Pharmaceuticals International, Inc. (NYSE: VRX and ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with ... indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for all ... Medical, Inc. (NASDAQ: SLTM ) ("Solta") at ...
(Date:1/15/2014)...  A novel wearable injector slightly larger than an Oreo cookie ... self-inject prescription drugs in the large doses required to treat ... deficiencies, and genetic disorders.  An emerging biologic ... according to analysts.   Many of these drugs will require a ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
(Date:4/17/2014)... University of California, San Diego School of Medicine report ... suffered a recent major loss are more likely to ... The study is published in this month,s issue of ... Because compassionate behaviors are associated with better health and ... into ways to improve the outcomes of individuals whose ...
(Date:4/17/2014)... the April issue of Immunity , Kevin J. ... Research, says it,s time to take a fresh look ... sepsis, which kills millions worldwide every year, including more ... into the bloodstream to fight an injury or infection ... maintaining good health without inflammation, wounds and infections ...
(Date:4/17/2014)... A Northwestern University synthetic biology team has created ... create programmable therapeutics that could travel the body ... disease. , Engineering cell-based, biological devices that monitor ... in clinical synthetic biology. However, no existing technology ... a patient,s physiological state and respond in a ...
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... YORK, NY (April 16, 2014) The cause of ... a new study proposes that neurons may be mistaken ... immune system, similar to the way autoimmune diseases like ... the body,s cells. The study was published April 16, ... a new, and likely controversial, idea in Parkinson,s disease; ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Is Parkinson's an autoimmune disease? 2
... the nation,s largest independent behavioral health and wellness ... Web site was honored with an eHealthcare ... Conference held November 10-12, 2008 in Orlando, FL. ... Award for Best Site Design for the second ...
... first half of 2009.SAN DIEGO, Jan. 6 Amira ... candidate for the treatment and control of inflammatory and ... on target for submission of an IND to the ... the successful completion of Good Laboratory Practices (GLP) toxicity ...
... available in French . , Montreal, ... risk delivering aggressive kids according to a new Canada-Netherlands ... . While previous studies have shown that smoking during ... who light up during pregnancy can predispose their offspring ...
... MOUNT VERNON, N.Y., Jan. 6 For over ... Prasad has,helped thousands of people including many celebrities ... innovative and highly effective treatment,program. His program combines ... with his trademark Turning Point Treatments to help ...
... and Benzoyl Peroxide in a Single Product; Performs ... 6 Galderma Laboratories, L.P. today announced the ... 0.1% / 2.5%, the first and only, once-daily, ... adapalene, and benzoyl peroxide, a well-known antimicrobial with ...
... (Nasdaq: COWN ) announced today that Christine Arnold ... care and health care service providers. Ms. Arnold joins Cowen ... from 1999 to 2008. She was previously employed by ... services. Between 2000 and 2008, she has consistently ranked ...
Cached Medicine News:Health News:ValueOptions(R) Behavioral Health and Wellness Web Site Wins eHealthcare Leadership Award for Best Site Design Second Year in a Row 2Health News:Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist. 2Health News:Smoking during pregnancy fosters aggression in children 2Health News:Stop Smoking in Three Sessions 2Health News:Galderma Announces Availability of Epiduo(TM) Gel, the First and Only Combination Treatment with a Retinoid and Benzoyl Peroxide to Treat Acne 2Health News:Galderma Announces Availability of Epiduo(TM) Gel, the First and Only Combination Treatment with a Retinoid and Benzoyl Peroxide to Treat Acne 3Health News:Galderma Announces Availability of Epiduo(TM) Gel, the First and Only Combination Treatment with a Retinoid and Benzoyl Peroxide to Treat Acne 4Health News:Cowen Adds Health Care Service Analyst to Equity Research Department 2
CCR Medical conventional laryngoscopes....
... Original LMA™ Airway., ,Launched in 1988, ... use is now standard practice in general ... worldwide the LMA Classic™ is a safe ... ,The LMA Classic™ can be used ...
... , ,Developed for cardiopulmonary resuscitation and ... LMA Fastrach™ has been designed to facilitate ... neck. The LMA Fastrach™ allows continuous ventilation ... emergency teams worldwide including NASA for its ...
... the production of airway management ... integrated solution to all your ... Portex Soft Seal Laryngeal Mask ... this wide portfolio of products ...
Medicine Products: